These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23204795)

  • 1. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
    Kang HK; Yoon MH; Lee DH; Chin HS
    Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
    Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population.
    Xu Y; Guan N; Xu J; Yang X; Ma K; Zhou H; Zhang F; Snellingen T; Jiao Y; Liu X; Wang N; Liu N
    Mol Vis; 2008 Jul; 14():1373-81. PubMed ID: 18682812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
    Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C; Oberkofler H; Ortner C; Paikl D; Riha W; Lang N; Patsch W; Egger SF
    Acta Ophthalmol; 2011 Jun; 89(4):e344-9. PubMed ID: 21232084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Park DH; Kim IT
    Retina; 2012 Feb; 32(2):299-307. PubMed ID: 21817962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.
    Park UC; Shin JY; McCarthy LC; Kim SJ; Park JH; Chung H; Yu HG
    Mol Vis; 2014; 20():1680-94. PubMed ID: 25558172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LOC387715/HTRA1 polymorphisms, smoking and combined effects on exudative age-related macular degeneration in a Korean population.
    Lee SJ; Kim NR; Chin HS
    Clin Exp Ophthalmol; 2010 Oct; 38(7):698-704. PubMed ID: 20456446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related macular degeneration and association of CFH Y402H and LOC387715 A69S polymorphisms in a Turkish population.
    Soysal Y; Inan UÜ; Küsbeci T; Imirzalioğlu N
    DNA Cell Biol; 2012 Mar; 31(3):323-30. PubMed ID: 21790300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population.
    Gotoh N; Yamada R; Nakanishi H; Saito M; Iida T; Matsuda F; Yoshimura N
    Clin Exp Ophthalmol; 2008 Jul; 36(5):437-42. PubMed ID: 18939352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of complement factor H Y402H, LOC387715, HTRA1 polymorphisms and ApoE alleles with susceptibility to age-related macular degeneration in Hungarian patients.
    Losonczy G; Fekete Á; Vokó Z; Takács L; Káldi I; Ajzner É; Kasza M; Vajas A; Berta A; Balogh I
    Acta Ophthalmol; 2011 May; 89(3):255-62. PubMed ID: 19845562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y402H polymorphism in complement factor H and age-related macular degeneration in the Tunisian population.
    Habibi I; Sfar I; Kort F; Aounallah-Skhiri H; Chebil A; Chouchene I; Bouraoui R; Limaiem R; Largheche L; Jendoubi-Ayed S; Makhlouf M; Ben Abdallah T; Ayed K; El Matri L; Gorgi Y
    Ophthalmic Res; 2013; 49(4):177-84. PubMed ID: 23306536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.
    Orlin A; Hadley D; Chang W; Ho AC; Brown G; Kaiser RS; Regillo CD; Godshalk AN; Lier A; Kaderli B; Stambolian D
    Retina; 2012 Jan; 32(1):4-9. PubMed ID: 21878851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.
    Chang W; Noh DH; Sagong M; Kim IT
    Mol Vis; 2013; 19():702-9. PubMed ID: 23559864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.
    Lee AY; Raya AK; Kymes SM; Shiels A; Brantley MA
    Br J Ophthalmol; 2009 May; 93(5):610-3. PubMed ID: 19091853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.
    Maguire MG; Daniel E; Shah AR; Grunwald JE; Hagstrom SA; Avery RL; Huang J; Martin RW; Roth DB; Castellarin AA; Bakri SJ; Fine SL; Martin DF;
    Ophthalmology; 2013 Oct; 120(10):2035-41. PubMed ID: 23706946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.
    Dikmetas O; Kadayıfcılar S; Eldem B
    Mol Vis; 2013; 19():2571-8. PubMed ID: 24367156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.